
Ensocell is a venture capital-backed Life Science company that leverages cutting-edge single cell genomics technologies, AI-based computational tools, and advanced cell models to identify novel disease intervention points and discover therapeutics for autoimmune, inflammatory, and fibrotic diseases. Founded by leading scientists at the Wellcome Sanger Institute, Ensocell operates from the Wellcome Genome Campus in Hinxton, UK, and San Francisco, USA, positioning itself at the forefront of biotechnology innovation with a mission to improve human health.

Ensocell is a venture capital-backed Life Science company that leverages cutting-edge single cell genomics technologies, AI-based computational tools, and advanced cell models to identify novel disease intervention points and discover therapeutics for autoimmune, inflammatory, and fibrotic diseases. Founded by leading scientists at the Wellcome Sanger Institute, Ensocell operates from the Wellcome Genome Campus in Hinxton, UK, and San Francisco, USA, positioning itself at the forefront of biotechnology innovation with a mission to improve human health.